Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
Exelixis (NASDAQ:EXEL) described its current commercial trajectory, late-stage clinical programs, and strategic priorities during a discussion at a Barclays event featuring Senior Vice President of Strategy and Investor Relations Andrew Peters. Peters emphasized that the company remains anchored by its lead product CABOMETYX (cabozantinib), while advancing a next-generation tyrosine kinase inhibitor (TKI), zanzalintinib, and a broader internal pipeline that includes both small molecules and biotherapeutics. Commercial foundation: CABOMETYX and growth drivers Peters said Exelixis is “a commercial oncology company” built around CABOMETYX, which he characterized as a TKI targeting VEGF as well as other kinases including MET, AXL, MER and the TAM kinases. He noted that cabozantinib has established approvals across multiple tumor types, including kidney cancer, liver cancer, thyroid cancer, and neuroendocrine tumors (NETs). ? Broadcom's AI Momentum Could Be Far From Over 3 Stocks
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion [Yahoo! Finance]Yahoo! Finance
- Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink [Yahoo! Finance]Yahoo! Finance
- Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference [Yahoo! Finance]Yahoo! Finance
- Here's Why Exelixis (EXEL) is a Strong Growth Stock [Yahoo! Finance]Yahoo! Finance
- Exelixis, Inc. (EXEL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
EXEL
Earnings
- 2/10/26 - Beat
EXEL
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- EXEL's page on the SEC website